Showing results (231-240 of 2,556) with videos related to
Sort By:
Pageof 256
Therapeutics and Clinical Risk Management|October 10, 2009
Dyslipidemia in Iranian overweight and obese childrenRobabeh GhergerehchiTherapeutics and Clinical Risk Management|February 18, 2014
Clinical differences between H3N2 and H1N1 influenza 2012 and lower respiratory tract infection found using a statistical classification approachDimitris Petridis, Paul Zarogoulidis, Anastasios Kallianos, et al.Therapeutics and Clinical Risk Management|January 27, 2017
The association of nephrolithiasis with metabolic syndrome and its components: a cross-sectional analysisYen-Tze Liu, Pei-Yu Yang, Yu-Wen Yang, et al.Therapeutics and Clinical Risk Management|April 3, 2019
Clinical efficacy and safety of anticholinergic therapies in pediatric patientsStanley GoldsteinTherapeutics and Clinical Risk Management|April 15, 2017
Drug-related problems in patients with erectile dysfunctions and multiple comorbiditiesHasniza Zaman Huri, Chui Fang Ling, Azad Hassan Abdul RazackTherapeutics and Clinical Risk Management|April 11, 2017
Evaluation of the clinical effect of small-volume resuscitation on uncontrolled hemorrhagic shock in emergencyGang Zhao, Wei Wu, Qi-Ming Feng, et al.Therapeutics and Clinical Risk Management|March 1, 2017
Intermittent pneumatic compression devices combined with anticoagulants for prevention of symptomatic deep vein thrombosis after total knee arthroplasty: a pilot studyPengcheng Liu, Junfeng Liu, Liyang Chen, et al.Therapeutics and Clinical Risk Management|March 1, 2017
In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Dembia District, northwest EthiopiaTekalign Deressa, Mengistu Endris Seid, Wubet Birhan, et al.Therapeutics and Clinical Risk Management|June 3, 2008
Review of tenofovir-emtricitabineSaba Woldemichael Masho, Cun-Lin Wang, Daniel E NixonTherapeutics and Clinical Risk Management|June 3, 2008
History and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agentsJoseph F John, Alexander M HarvinPageof 256